Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Add as a preferred source on Google
BOSTON, May 07, 2018 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update.
To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (international) and refer to conference ID: 4076397. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
[email protected]
